Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean Wingerchuk

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Ebiomedicine|November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.
Journal of Neurology|November 5, 2015
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesMaciej Juryńczyk, Brian Weinshenker, Gulsen Akman-Demir, et al.
JAMA Neurology|May 27, 2015
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderStephane Kremer, Felix Renard, Sophie Achard, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 4, 2015
Update on biomarkers in neuromyelitis opticaEsther Melamed, Michael Levy, Patrick J Waters, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Ebiomedicine|November 12, 2022
Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trialJeffrey L Bennett, Orhan Aktas, William A Rees, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 4, 2021
Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSDBruce Ac Cree, Jeffrey L Bennett, Ho Jin Kim, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 27, 2021
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Jeffrey L Bennett, Ho Jin Kim, et al.
Journal of Neurology|November 5, 2015
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesMaciej Juryńczyk, Brian Weinshenker, Gulsen Akman-Demir, et al.
JAMA Neurology|May 27, 2015
Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum DisorderStephane Kremer, Felix Renard, Sophie Achard, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 4, 2015
Update on biomarkers in neuromyelitis opticaEsther Melamed, Michael Levy, Patrick J Waters, et al.
Pageof 2